إسرائيل - العبرية - Ministry of Health

cts chemical industries ltd, israel - montelukast as sodium - טבליות לעיסות - montelukast as sodium 4 mg - montelukast - montelukast - take air is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. take air is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. take air and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. take air is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

إسرائيل - العبرية - Ministry of Health

cts chemical industries ltd, israel - montelukast as sodium - טבליות לעיסות - montelukast as sodium 5 mg - montelukast - montelukast - take air is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. take air is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. take air and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. take air is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

إسرائيل - العبرية - Ministry of Health

trima israel pharmaceutical products maabarot ltd - montelukast as sodium salt - טבליות לעיסות - montelukast as sodium salt 4 mg - montelukast - montelukast - montelukast - trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. montelukast - trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast - trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast - trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

إسرائيل - العبرية - Ministry of Health

trima israel pharmaceutical products maabarot ltd - montelukast as sodium salt - טבליות לעיסות - montelukast as sodium salt 5 mg - montelukast - montelukast - montelukast - trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. montelukast - trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast - trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast - trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

إسرائيل - العبرية - Ministry of Health

trima israel pharmaceutical products maabarot ltd - montelukast as sodium salt - טבליה - montelukast as sodium salt 10 mg - montelukast - montelukast - montelukast - trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. montelukast - trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast - trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast - trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

إسرائيل - العبرية - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 500 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

إسرائيل - العبرية - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

إسرائيل - العبرية - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

إسرائيل - العبرية - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

إسرائيل - العبرية - Ministry of Health

teva israel ltd - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa